JP2014042533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014042533A5 JP2014042533A5 JP2013250586A JP2013250586A JP2014042533A5 JP 2014042533 A5 JP2014042533 A5 JP 2014042533A5 JP 2013250586 A JP2013250586 A JP 2013250586A JP 2013250586 A JP2013250586 A JP 2013250586A JP 2014042533 A5 JP2014042533 A5 JP 2014042533A5
- Authority
- JP
- Japan
- Prior art keywords
- pseudomonas aeruginosa
- host cell
- recombinant
- protein
- coli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 14
- 241000588724 Escherichia coli Species 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 108091035707 Consensus sequence Proteins 0.000 claims 3
- 101710116435 Outer membrane protein Proteins 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 241000589875 Campylobacter jejuni Species 0.000 claims 2
- 241000205834 Escherichia coli O16 Species 0.000 claims 2
- 108010079246 OMPA outer membrane proteins Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 241000205838 Escherichia coli O9 Species 0.000 claims 1
- 235000019687 Lamb Nutrition 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 108700028353 OmpC Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05010276 | 2005-05-11 | ||
| EP05010276.3 | 2005-05-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012001342A Division JP5687637B2 (ja) | 2005-05-11 | 2012-01-06 | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014042533A JP2014042533A (ja) | 2014-03-13 |
| JP2014042533A5 true JP2014042533A5 (enExample) | 2014-05-08 |
| JP5827303B2 JP5827303B2 (ja) | 2015-12-02 |
Family
ID=37396912
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510495A Active JP5356807B2 (ja) | 2005-05-11 | 2006-05-10 | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
| JP2012001342A Active JP5687637B2 (ja) | 2005-05-11 | 2012-01-06 | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
| JP2013250586A Active JP5827303B2 (ja) | 2005-05-11 | 2013-12-03 | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510495A Active JP5356807B2 (ja) | 2005-05-11 | 2006-05-10 | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
| JP2012001342A Active JP5687637B2 (ja) | 2005-05-11 | 2012-01-06 | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8753864B2 (enExample) |
| EP (3) | EP2853600B1 (enExample) |
| JP (3) | JP5356807B2 (enExample) |
| KR (2) | KR101524636B1 (enExample) |
| CN (2) | CN101360831B (enExample) |
| AT (1) | ATE483027T1 (enExample) |
| AU (1) | AU2006245969B8 (enExample) |
| CA (1) | CA2607595C (enExample) |
| CY (1) | CY1116285T1 (enExample) |
| DE (1) | DE602006017207D1 (enExample) |
| DK (2) | DK2311972T3 (enExample) |
| ES (3) | ES2535084T3 (enExample) |
| HK (1) | HK1205193A1 (enExample) |
| HR (1) | HRP20150312T1 (enExample) |
| IL (2) | IL187293A (enExample) |
| PL (1) | PL2311972T3 (enExample) |
| PT (2) | PT1888761E (enExample) |
| SI (1) | SI2311972T1 (enExample) |
| WO (1) | WO2006119987A2 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| CA2477794C (en) | 2002-03-07 | 2013-08-20 | Eidgenoessische Technische Hochschule Zuerich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| JP5743368B2 (ja) | 2004-01-08 | 2015-07-01 | ラショファーム ゲーエムベーハー | ペプチドのｏ結合型グリコシル化 |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| AU2005251676B2 (en) * | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| BRPI0608249A2 (pt) * | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
| EP1871795A4 (en) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE |
| EP1891231A4 (en) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| RS52845B (sr) | 2007-04-03 | 2013-12-31 | Biogenerix Ag | Postupci tretmana korišćenjem glikopegiliranog g-csf |
| JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | ヌクレオチド糖の改良製造法 |
| US8999668B2 (en) | 2008-01-03 | 2015-04-07 | Cornell Research Foundation, Inc. | Glycosylated protein expression in prokaryotes |
| EP2242505A4 (en) * | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
| HRP20181259T1 (hr) * | 2008-02-20 | 2018-10-05 | Glaxosmithkline Biologicals S.A. | Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica |
| ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
| PL2411503T3 (pl) * | 2009-03-27 | 2018-01-31 | Eidgenoessische Technische Hochschule Zuerich | Salmonella enterica prezentująca n-glikan z c. jejuni lub jego pochodne |
| AU2010322454B2 (en) * | 2009-11-19 | 2016-05-19 | Glaxosmithkline Biologicals S.A. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| JP5925699B2 (ja) | 2010-02-11 | 2016-05-25 | ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ | Ｎ結合型グリカン化合物 |
| ES2844596T3 (es) * | 2010-05-06 | 2021-07-22 | Glaxosmithkline Biologicals Sa | Vacunas de bioconjugados de bacterias grampositivas capsulares |
| JP2013539963A (ja) * | 2010-09-03 | 2013-10-31 | ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ | 複数のｎ結合型グリコシル化シークオンを含んでいるペプチド |
| AU2012306345A1 (en) | 2011-09-06 | 2014-03-20 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
| SG11201503308XA (en) | 2012-11-07 | 2015-05-28 | Glycovaxyn Ag | PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION |
| BR112015014991B1 (pt) | 2013-01-17 | 2024-01-23 | Janssen Pharmaceuticals, Inc | Anticorpo específico para e. coli mdr, plasmídeo, cassete de expressão, célula hospedeira, método de produção do anticorpo, método para identificar um anticorpo candidato, preparação farmacêutica e de diagnóstico, epítopo, imunogênio e ácido nucleico utilizados |
| CA2923957C (en) | 2013-01-18 | 2021-08-31 | London School Of Hygiene And Tropical Medicine | Glycosylation method |
| GB201301085D0 (en) | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
| BR112015022849B1 (pt) * | 2013-03-15 | 2020-02-18 | Asieris Pharmaceutical Technologies Co., Ltd. | Sais de adição de base de nitroxolina, usos e processo para preparação dos mesmos, bem como seu cristal, composição farmacêutica e processo para preparação da mesma |
| EP2991675B1 (en) * | 2013-04-05 | 2019-07-24 | The Governors of the University of Alberta | Campylobacter vaccine |
| US11220676B2 (en) * | 2013-10-11 | 2022-01-11 | Glaxosmithkline Biological Sa | Methods of host cell modification |
| EA035991B9 (ru) | 2014-02-24 | 2020-10-21 | Глаксосмитклайн Байолоджикалс С.А. | Новый полисахарид и его применения |
| SI3131577T1 (sl) | 2014-04-17 | 2020-08-31 | Glaxosmithkline Biologicals S.A. | Modificirane gostiljske celice in uporabe le-teh |
| SG11201700325SA (en) | 2014-08-08 | 2017-02-27 | Glycovaxyn Ag | Modified host cells and hybrid oligosaccharides for use in bioconjugate production |
| SI3240895T1 (sl) * | 2014-12-30 | 2022-04-29 | Glaxosmithkline Biologicals S.A. | Sestavki in postopki za glikozilacijo proteinov |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| GB201518668D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| WO2017117539A1 (en) | 2015-12-30 | 2017-07-06 | Northwestern University | Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| US10829795B2 (en) | 2016-07-14 | 2020-11-10 | Northwestern University | Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| EP3573654A4 (en) * | 2017-01-27 | 2020-11-25 | University of Florida Research Foundation, Incorporated | FOOD SAFETY VACCINE TO CONTROL SALMONELLA ENTERICA AND REDUCE CAMPYLOBACTER IN POULTRY |
| GB201712678D0 (en) | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| US11898187B2 (en) | 2017-08-15 | 2024-02-13 | Northwestern University | Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| TW201946650A (zh) | 2018-03-12 | 2019-12-16 | 美商詹森藥物公司 | 針對腹內感染之疫苗 |
| US11530432B2 (en) | 2018-03-19 | 2022-12-20 | Northwestern University | Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates |
| US11725224B2 (en) | 2018-04-16 | 2023-08-15 | Northwestern University | Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates |
| WO2020072127A2 (en) | 2018-08-03 | 2020-04-09 | Northwestern University | On demand, portable, cell-free molecular sensing platform |
| WO2020120569A2 (en) | 2018-12-12 | 2020-06-18 | Glaxosmithkline Biologicals Sa | Modified carrier proteins for o-linked glycosylation |
| US12404533B2 (en) | 2019-01-11 | 2025-09-02 | Northwestern University | Bioconjugate vaccines' synthesis in prokaryotic cell lysates |
| US12325884B2 (en) | 2019-03-04 | 2025-06-10 | Northwestern University | Riboswitch-based fluoride sensing in cell-free extract |
| IL286467B1 (en) | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them |
| MY205586A (en) * | 2019-03-18 | 2024-10-28 | Janssen Pharmaceuticals Inc | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
| EP3757217A1 (en) | 2019-06-27 | 2020-12-30 | GlaxoSmithKline Biologicals S.A. | Methods for protein purification |
| EP3770269A1 (en) * | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| US12226410B2 (en) | 2019-10-18 | 2025-02-18 | Northwestern University | Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6 |
| WO2021144369A1 (en) | 2020-01-16 | 2021-07-22 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
| CA3185719A1 (en) | 2020-06-18 | 2021-12-23 | Glaxosmithkline Biologicals Sa | Shigella-tetravalent (shigella4v) bioconjugate |
| US20230293657A1 (en) | 2020-06-25 | 2023-09-21 | Glaxosmithkline Biologicals Sa | Vaccine |
| KR20230043157A (ko) | 2020-09-17 | 2023-03-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 다가 백신 조성물 및 이의 용도 |
| TW202241929A (zh) | 2021-01-12 | 2022-11-01 | 美商詹森藥物公司 | ＦｉｍＨ突變體、其組成物及其用途 |
| CA3215752A1 (en) | 2021-04-01 | 2022-10-06 | Janssen Pharmaceuticals, Inc. | Production of e. coli o18 bioconjugates |
| EP4452308A1 (en) | 2021-12-22 | 2024-10-30 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2025032534A2 (en) | 2023-08-09 | 2025-02-13 | Glaxosmithkline Biologicals Sa | Modified proteins |
| WO2025032535A2 (en) | 2023-08-09 | 2025-02-13 | Glaxosmithkline Biologicals Sa | Modified proteins |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170204B1 (de) | 1984-08-01 | 1991-09-25 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen |
| US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| EP0726318A1 (en) | 1993-05-14 | 1996-08-14 | The Upjohn Company | An acceptor polypeptide for an N-acetylgalactosaminyltransferase |
| US6503744B1 (en) | 1999-02-01 | 2003-01-07 | National Research Council Of Canada | Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics |
| CA2363297C (en) | 1999-03-02 | 2011-08-09 | Michael J. Betenbaugh | Engineering intracellular sialylation pathways |
| US20020127219A1 (en) * | 1999-12-30 | 2002-09-12 | Okkels Jens Sigurd | Lysosomal enzymes and lysosomal enzyme activators |
| NZ522320A (en) | 2000-05-12 | 2007-03-30 | Neose Technologies Inc | In vitro modification of glycosylation patterns of recombinant glycopeptides |
| EP2267135A3 (en) | 2000-06-30 | 2011-09-14 | Vib Vzw | Protein glycosylation modification in pichia pastoris |
| DE10113573A1 (de) | 2001-03-20 | 2002-02-28 | Messer Griesheim Gmbh | Verfahren zum Regenerieren von Schwefelsäure aus schwefelhaltigen Reststoffen |
| CA2477794C (en) * | 2002-03-07 | 2013-08-20 | Eidgenoessische Technische Hochschule Zuerich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| KR20130101592A (ko) | 2002-03-07 | 2013-09-13 | 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 | 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계 |
| CN1671722A (zh) * | 2002-08-01 | 2005-09-21 | 加拿大国家研究院 | 弯曲菌的聚糖和糖肽 |
-
2006
- 2006-05-10 JP JP2008510495A patent/JP5356807B2/ja active Active
- 2006-05-10 AU AU2006245969A patent/AU2006245969B8/en active Active
- 2006-05-10 SI SI200631910T patent/SI2311972T1/sl unknown
- 2006-05-10 EP EP14199949.0A patent/EP2853600B1/en active Active
- 2006-05-10 AT AT06753552T patent/ATE483027T1/de active
- 2006-05-10 KR KR1020147001671A patent/KR101524636B1/ko active Active
- 2006-05-10 DE DE602006017207T patent/DE602006017207D1/de active Active
- 2006-05-10 ES ES10179208.3T patent/ES2535084T3/es active Active
- 2006-05-10 PT PT06753552T patent/PT1888761E/pt unknown
- 2006-05-10 ES ES06753552T patent/ES2353814T3/es active Active
- 2006-05-10 PT PT101792083T patent/PT2311972E/pt unknown
- 2006-05-10 ES ES14199949T patent/ES2703061T3/es active Active
- 2006-05-10 CN CN200680020861XA patent/CN101360831B/zh active Active
- 2006-05-10 PL PL10179208T patent/PL2311972T3/pl unknown
- 2006-05-10 DK DK10179208T patent/DK2311972T3/en active
- 2006-05-10 DK DK06753552.6T patent/DK1888761T3/da active
- 2006-05-10 EP EP10179208.3A patent/EP2311972B1/en active Active
- 2006-05-10 WO PCT/EP2006/004397 patent/WO2006119987A2/en not_active Ceased
- 2006-05-10 US US11/920,175 patent/US8753864B2/en active Active
- 2006-05-10 KR KR1020077028970A patent/KR101408653B1/ko active Active
- 2006-05-10 CN CN201310241471.7A patent/CN103396478B/zh active Active
- 2006-05-10 EP EP06753552A patent/EP1888761B1/en active Active
- 2006-05-10 CA CA2607595A patent/CA2607595C/en active Active
-
2007
- 2007-11-11 IL IL187293A patent/IL187293A/en active IP Right Grant
-
2012
- 2012-01-06 JP JP2012001342A patent/JP5687637B2/ja active Active
-
2013
- 2013-06-10 IL IL226857A patent/IL226857A/en not_active IP Right Cessation
- 2013-12-03 JP JP2013250586A patent/JP5827303B2/ja active Active
-
2014
- 2014-02-06 US US14/174,742 patent/US9551019B2/en active Active
-
2015
- 2015-03-18 HR HRP20150312TT patent/HRP20150312T1/hr unknown
- 2015-04-15 CY CY20151100351T patent/CY1116285T1/el unknown
- 2015-06-09 HK HK15105466.7A patent/HK1205193A1/en unknown
-
2016
- 2016-05-19 US US15/159,535 patent/US20160326563A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014042533A5 (enExample) | ||
| Carvalho et al. | Bioengineering commensal bacteria-derived outer membrane vesicles for delivery of biologics to the gastrointestinal and respiratory tract | |
| Shehata et al. | Bacterial outer membrane vesicles (OMVs)-based dual vaccine for influenza A H1N1 virus and MERS-CoV | |
| LeCureux et al. | Lactobacillus mucosal vaccine vectors: immune responses against bacterial and viral antigens | |
| Browning et al. | The central role of lipoproteins in the pathogenesis of mycoplasmoses | |
| JP2016539946A5 (enExample) | ||
| JP6687585B2 (ja) | 免疫応答を増強するワクチンベクターおよび方法 | |
| JP2008529558A5 (enExample) | ||
| Robinson | Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology | |
| Villena et al. | Lactiplantibacillus plantarum as a potential adjuvant and delivery system for the development of SARS-CoV-2 oral vaccines | |
| Wan et al. | Rational design of a chimeric derivative of PcrV as a subunit vaccine against Pseudomonas aeruginosa | |
| CN105142653B (zh) | 增强对肠病原体免疫应答的组合物和方法 | |
| JP2011500073A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| Jiang et al. | A phase trial of the oral Lactobacillus casei vaccine polarizes Th2 cell immunity against transmissible gastroenteritis coronavirus infection | |
| US20210252081A1 (en) | Immunogenic composition | |
| JP2019500026A5 (enExample) | ||
| Yu et al. | Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71 | |
| PH12013501373B1 (en) | Bovine viral diarrhea virus type 1b vaccine compositions and methods | |
| JP2010532656A5 (enExample) | ||
| CN107073073B (zh) | 经肺施用绿脓菌素用于治疗细菌性呼吸道感染 | |
| US10953078B2 (en) | Treatment and/or prevention of sepsis | |
| Wang et al. | Neutralizing-antibody-mediated protection of chickens against infectious bursal disease via one-time vaccination with inactivated recombinant Lactococcus lactis expressing a fusion protein constructed from the RCK protein of Salmonella enterica and VP2 of infectious bursal disease virus | |
| JP2013515490A5 (enExample) | ||
| CN104994871B (zh) | 针对流感的多价融合蛋白疫苗 |